NEXT Financial Group Inc decreased its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 27.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,777 shares of the pharmaceutical company’s stock after selling 3,619 shares during the quarter. NEXT Financial Group Inc’s holdings in GlaxoSmithKline PLC were worth $401,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. FMR LLC boosted its position in shares of GlaxoSmithKline PLC by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of GlaxoSmithKline PLC by 2.3% during the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after acquiring an additional 293,866 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of GlaxoSmithKline PLC by 112.1% during the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GlaxoSmithKline PLC by 4.3% during the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after acquiring an additional 322,700 shares during the last quarter. Finally, Federated Investors Inc. PA boosted its position in shares of GlaxoSmithKline PLC by 22.7% during the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after acquiring an additional 833,501 shares during the last quarter. Hedge funds and other institutional investors own 9.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “NEXT Financial Group Inc Reduces Position in GlaxoSmithKline PLC (GSK)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/21/next-financial-group-inc-reduces-position-in-glaxosmithkline-plc-gsk.html.

A number of equities analysts recently weighed in on the stock. Investec lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Bank of America Corporation lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, October 24th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $44.33.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded down $0.22 on Tuesday, hitting $34.90. 2,800,127 shares of the stock traded hands, compared to its average volume of 3,443,483. GlaxoSmithKline PLC has a 1-year low of $34.72 and a 1-year high of $44.53. The stock has a market capitalization of $85,170.00, a P/E ratio of 12.43, a P/E/G ratio of 1.94 and a beta of 1.00. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be paid a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.77%. The ex-dividend date is Thursday, November 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 157.94%.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of GlaxoSmithKline PLC stock in a transaction that occurred on Monday, November 6th. The shares were bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 10.00% of the company’s stock.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.